Dr. Bauml Discusses Immunotherapy in Head and Neck Cancer

Joshua Bauml, MD
Published: Tuesday, Jul 18, 2017



Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy in head and neck cancer.

Bauml says that immunotherapy has a key role to play in the treatment of head and neck cancer. The arrival of PD-1 inhibitors, especially for patients with metastatic disease, has brought promise to the treatment landscape.

Specifically, Bauml says, head and neck cancer has overregulation of PD-L1 and PD-L2, as well as being virally mediated, making it an appropriate setting for immunotherapy.
 


Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy in head and neck cancer.

Bauml says that immunotherapy has a key role to play in the treatment of head and neck cancer. The arrival of PD-1 inhibitors, especially for patients with metastatic disease, has brought promise to the treatment landscape.

Specifically, Bauml says, head and neck cancer has overregulation of PD-L1 and PD-L2, as well as being virally mediated, making it an appropriate setting for immunotherapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x